Reactive oxygen species (ROS) have been implicated in the pathogenesis of a wide range of human disease states and drug toxicities, but development of imaging tools to study ROS biology in vivo remains a challenge. Here we synthesized and validated a novel PET tracer (12) 
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Introduction
Chronic inflammatory response in multiple diseases results in the activation of innate immune enzymes such as NADPH oxidase to produce reactive oxygen species (ROS), which in turn have been shown in animal models to contribute to tissue injury, fibrosis, remodeling and organ dysfunction for a range of pathology and disease. ROS are produced by normal cellular metabolism, and are fundamental to cell biology in a broad sense. However, while ROS are involved in all aspects of normal cellular function, disruption of the physiological balance in ROS homeostasis caused by disease, injury, or environmental stress (e.g., ionizing radiation, UV and heat exposure) can lead to inappropriate cell signaling, dysfunction, and overt cell death. At the organ level, these pathological responses to ROS can produce inflammation, fibrosis, tissue remodeling, and trigger other deleterious cascades in diseases processes such as ischemia and reperfusion of heart, lung, brain and kidney [1] [2] [3] [4] [5] , neurodegenerative diseases including Parkinson's disease, Amyotrophic Later Sclerosis (ALS) and Alzheimer's disease [6] [7] [8] [9] , as well as end-organ fibrosis and failure in diabetes 10 . Collectively, ROS comprise the chemically reactive products of molecular oxygen (O2) including the one-electron reduction product of molecular oxygen:
superoxide (O2 -) 11 . Superoxide can be produced by a number of sources in vivo, including the mitochondrial electron transport chain and NADPH oxidase(s), which are activated under conditions of inflammation, ischemia, and tissue injury. Superoxide has been shown to regulate distinct signaling cascades and to have specific molecular targets. The ability to detect elevated ROS in the intact animal or patient would provide a better understanding of the links between ROS, tissue injury, and disease. Furthermore, the ability to selectively identify the ROS being generated will be critical to understanding the molecular cascades affected.
A variety of methods for evaluating ROS in cell culture and tissue slices have been developed, and these approaches have advanced our understanding of both the physiological role of ROS as signaling molecules and necessary intermediates in cell metabolism, and as toxic species which can damage cells and tissues. Techniques currently employed include chemiluminescence assays 12, 13 , electron spin resonance (ESR) using nitrone or nitroxide spin traps 14 , and fluorescencebased techniques with oxidizable fluorescent probes such as Peroxy Green 1, Peroxy Crimson 1 15, 16 , 2,7-dichlorodihydrogluorescein diacetate (DCFH-DA) [17] [18] [19] [20] , dihydrorhodamine 123 (DHR) 21 , hydrocyanines 22, 23 (see Supporting Information, Figure S1 ), and dihydroethidium (DHE, Figure   1 ) and its analogs [24] [25] [26] [27] [28] [29] [30] . Although there is an unmet need for imaging tools to study the production of metabolic and inflammatory ROS and/or reactive nitrogen species (RNS) in humans or animal models, some considerable difficulties must be overcome to develop such tools. First, ROS (and RNS) are small molecules which have a relatively short lifetime, so it cannot be detected by conventional "radioligand bound to target" strategies. Second, fluorescence, chemiluminescence, optical, and electron spin resonance imaging are limited in their ability to measure in vivo intracellular ROS due to substantial attenuation of the output signal by the tissue within a few centimeters. Given the drawbacks in the use of these probes, especially for imaging in vivo ROS production in an intact animal or human, an alternative, sensitive method for detecting superoxide produced in a variety of biological systems is needed.
Positron emission tomography (PET) is a noninvasive imaging technique capable of measuring specific chemical or enzymatic reactions in tissues in vivo. Therefore, a radiolabeled DHE analog as a PET tracer to image ROS in vivo could overcome the disadvantages of existing DHE-based fluorescence probes. Like DHE, a DHE analog used as a PET radiotracer will not bind to DNA because it is a neutral molecule and its phenanthridine moiety has a nonplanar geometry. However, the oxidation products of the DHE analog by ROS, ethidium or 2-OH ethidium analogs, can bind to DNA since these products possess a positive charge and the corresponding phenanthridine ring system has a planar geometry. Once these positively-charged oxidized analogs bind to DNA in cells, they become trapped and are retained within the cell for a longer duration while the parent DHE analog washes out of the cell rapidly. This difference in retention provides a method to quantify ROS levels in vivo by PET imaging. To date, there have been no reported noninvasive or minimally invasive methods to evaluate ROS in the intact organism using PET. Here, we report the novel development of a PET-based DHE analog which could be used as a radiotracer for imaging superoxide levels in vivo.
Results and discussion
Synthesis of 10 and 12
The synthesis of standard compound 12 and the precursor compound 10 are shown in Scheme 1 and Scheme 2. The 4,4'-dinitrobiphenyl-2-amine (1) and 4-methoxybenzoyl chloride were heated in chlorobenzene to give compound 2. The nitro groups of 2 were reduced to amines with ammonium formate using Pd(OH)2 as a catalyst to afford 3. The amine groups of 3 were protected with methyl carbamate, then cyclized with POCl3 to give 4 and 5, respectively. Compound 5 was deprotected with 48% HBr under reflux to afford the intermediate 6.
The amine groups of 6 were protected with t-butyl carbamate, and the OH group of the phenol was propynylated with 3-bromoprop-1-yne using K2CO3 as a base to give 7 and 8, respectively. Compound 8 was methylated with CH3I in THF to afford 9, which was reduced with NaBH3CN to give the precursor compound 10. Compound 10 underwent copper (I)-assisted 1,3-dipolar cycloaddition with 2-fluoroethyl azide (i.e., the "Click reaction") to yield 11, then the Boc group was deprotected to provide the DHE analog 12. Compound 14, the oxidized form of 12, was similarly synthesized from the intermediate 9 by Click reaction to afford 13, followed by deprotection of the Boc groups to give 14.
Selectivity studies
After compound 12 was synthesized, its selective reactivity with different reactive oxygen species was investigated and compared to results obtained with DHE in a fluorescence plate reader assay.
Compound 12 was oxidized by superoxide generated through either xanthine oxidase metabolism of hypoxanthine or by thermal decomposition of SIN-1 in the presence of CPTIO. In the both test systems, oxidation of compound 12 was completely prevented by the addition of superoxide dismutase (SOD) (Figure 2 ). Compound 12 was also exposed to H2O2 alone or in the presence of horseradish peroxidase (HRP) to generate hydroxyl free radical. The fluorescence intensity results indicate that compound 12 has little reactivity with hydroxyl radical (Figure 2) , or H2O2. These data suggest that 12 has good selectivity for superoxide.
Cell studies
As with DHE, compound 12 has no fluorescence at 595 nm, but its oxidized form 14 has very strong fluorescence at 595 nm (data not shown). Therefore, fluorescence at 595 nm can be used as 
Radiolabeling of 12
The of the radioactive counts in heart was similar between treated and untreated mice. However, 1 h later, the radioactive uptake was on average ~2 fold higher in the DOX-treated mice in heart than that in the control hearts (n=4) ( Figure 5 ). Post-microPET biodistribution data were obtained to further confirm the microPET results (see Supporting Information, Figure S5 ), and these data were in good agreement with the microPET data in that the radioactive uptake in the heart of DOXtreated mice was higher than that of control mice. Figure 5 ). The background uptake may be attributed to non-specific uptake and binding of [ 18 F]14 to DNA, proteins and other moieties due to its electrostatic charge.
Discussion
It is currently believed that elevated levels of ROS such as superoxide play a contributing role in a wide variety of pathological conditions. However, much of the evidence supporting this hypothesis has been generated in cellular or animal models of disease using fluorescent, chemiluminescent, and optical imaging techniques to measure ROS levels. Although valuable information has been gained in these preclinical studies, there is a need to develop a strategy for measuring ROS levels which could be used in translational imaging studies in humans. The goal of the current study was to develop a radiotracer which could be used to study disease-associated increases in ROS with the molecular imaging technique, PET. For this study, we synthesized a 18 F-labeled analog of DHE (i.e., [ 18 F]12) a well-characterized fluorescent probe for measuring superoxide levels in vitro and in vivo, and conducted a series of studies aimed at characterizing its ability to measure ROS in vivo with PET. The results of our in vitro studies suggest that compound 12 behaves in a manner very similar to DHE. That is, the parent, neutral compound crosses the cell membrane and is oxidized by ROS (i.e., superoxide) to form a planar, permanently charged species which is retained in the cell by intercalation into DNA.
DOX is a highly effective anticancer drug that is frequently employed to treat hematological and solid tumors including leukemia, breast cancer, and soft tissue sarcomas. However, the therapeutic effectiveness of DOX is compromised by its dose dependent and cumulative cardiotoxic side effects which include cardiomyopathy. The mechanisms responsible for DOX-induced cardiomyopathy remain unclear, but it is widely accepted that the DOX-induced cardiotoxicity is mainly attributed to the initial formation of superoxide and other ROS [33] [34] [35] . It has previously been reported that DOX induces NADPH oxidase-2 (Nox2, the respiratory burst oxidase) in heart muscle. Therefore, DOX-induced ROS production in the mouse heart provided a valuable model The 60 min biodistribution data indicate the DOX-treated mice have a two-fold higher retention in heart tissue compared to untreated mice, which is consistent with the results of the microPET study. In order to further confirm that the radioactive species in the hearts of DOX-treated mice In conclusion, abnormal production or inadequate elimination of ROS has been linked to a broad array of disease conditions, including Alzheimer's disease, diabetes, heart failure, cancer, neurodegeneration and the aging process itself. The pharmaceutical industry has actively pursued therapeutic attempts to diminish oxidative stress produced by ROS in patients and in animal models of disease. There is a growing consensus that there is a need to develop tools which will allow researchers to better understand the temporal, spatial, and biochemical contributions of ROS to normal biology as well as disease pathology. 
Experimental Section General methods and materials
All chemicals were obtained from standard commercial sources and used without further purification. All reactions were carried out using standard air-free and moisture-free techniques under an inert nitrogen atmosphere with dry solvents unless otherwise stated. Flash column chromatography was conducted using Scientific Adsorbents, Inc. silica gel, 60A, "40 Micron 
N-(4,4'-Diaminobiphenyl-2-yl)-4-methoxybenzamide (3)
A mixture of 2 (3.93 g, 10.0 mmol), ammonium formate (6.31 g, 100 mmol), and 20% Pd(OH)2/C (200 mg) in methanol (50 mL) and ethyl acetate (50 mL) was heated to reflux for 3 h. The catalyst was filtered out through celite, and the filtrate was evaporated under reduced pressure. The crude product was dissolved in ethyl acetate (100 mL), washed with saturated NaHCO3 (50 mL), water (50 mL), NaCl (50 mL), and dried over Na2SO4. 
4-(3,8-Diaminophenanthridin-6-yl)phenol (6)
A solution of 5 (1.73 g, 4 mmol) in 48% HBr (100 mL) was heated under reflux for 3 days, then neutralized with Na2CO3 to pH=8, and extracted with CH2Cl2 (50 mL x 2); the combined CH2Cl2 was washed with water (50 mL), NaCl (50 mL) and dried over Na2SO4. (1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl) 
Radiosynthesis of [ 18 F]12
Deprotection of 10: Into a 10 mL Pyrex tube with screw cap was loaded 10 (2 mg, 3.51 µmol).
The tube was flushed with argon before and after the addition of TFA (500 µL) and ascorbic acid (1 mg, 5.68 µmol) in water (100 µL), and then the tube was capped and wrapped with aluminum foil. The tube was shaken to dissolve 10, and the reaction was allowed to proceed at ambient temperature for 15 min. TFA and water were then removed under vacuum (~ 1 torr) at ambient temperature to afford 17 as a pale yellow residue. This was done 1 h before labeling.
: DMF (300 µL) and N, N-diisopropylethylamine (10 µL) were added to the previously prepared tube to dissolve 17, and then the tube was cooled in a dry ice trap. 
